STOCK TITAN
  1. Home
  2. News
  3. CRSP

CRISPR Therapeutics AG - CRSP STOCK NEWS

Welcome to our dedicated page for CRISPR Therapeutics news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on CRISPR Therapeutics stock.

CRISPR Therapeutics AG (symbol: CRSP) is a pioneering gene editing company dedicated to the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. This revolutionary technology allows for precise, directed changes to genomic DNA, enabling the treatment of genetically defined diseases.

The company's portfolio spans a broad range of therapeutic programs, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. One of its notable achievements is the development and approval of Casgevy, a therapeutic targeting sickle cell disease and transfusion-dependent beta-thalassemia, developed in collaboration with Vertex Pharmaceuticals.

To bolster its research and development, CRISPR Therapeutics has forged strategic partnerships with renowned companies such as Bayer, Vertex Pharmaceuticals, and ViaCyte, Inc. These collaborations aim to accelerate and expand the company's efforts in bringing novel therapies to market.

Headquartered in Zug, Switzerland, CRISPR Therapeutics operates through its wholly-owned U.S. subsidiary, with R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California, and London, United Kingdom.

The company's ongoing projects include advancing gene editing programs in immuno-oncology and developing stem cell-derived therapies for the treatment of Type 1 diabetes. With its innovative approach and strategic collaborations, CRISPR Therapeutics is at the forefront of the gene editing revolution, poised to make significant impacts in the field of medicine.

For more information, please visit www.crisprtx.com.

News

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Rhea-AI Summary
CRISPR Therapeutics is set to present an oral presentation at the American Society of Gene & Cell Therapy 2024 Annual Meeting, showcasing their lipid nanoparticle approach for ocular editing. The presentation will focus on the potential treatment for glaucoma by targeting the MYOC gene, with promising results of up to 95% editing and 85% protein knockdown in human cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
conferences
-
News

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

Rhea-AI Summary
CRISPR Therapeutics to present at Needham Virtual Healthcare Conference on April 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
-
News

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Rhea-AI Summary
CRISPR Therapeutics announces an oral presentation at the ASGCT 2024 Annual Meeting on the Development of an In Vivo Non-Viral Ocular Editing Platform for Glaucoma treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
conferences
News

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Rhea-AI Summary
CRISPR Therapeutics (CRSP) announces the proposal to elect Christian Rommel, Ph.D., to its Board of Directors, bringing valuable experience in drug innovation and development. Dr. Rommel's expertise is expected to enhance CRISPR's platform and pipeline for creating gene-based medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
management
-
News

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
CRISPR Therapeutics achieves significant milestones in gene-based medicines with multiple clinical trials ongoing and a strengthened balance sheet through a $280 million offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
earnings
-
News

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

Rhea-AI Summary
CRISPR Therapeutics (CRSP) to present at Citi 2024 Virtual Oncology Leadership Summit, offering a live webcast and replay option for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.88%
Tags
conferences
News

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

Rhea-AI Summary
CRISPR Therapeutics (CRSP) secures $280 million investment to advance clinical trials and gene writing programs, strengthening balance sheet with over $2.1 billion in pro forma cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
offering
-
News

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

Rhea-AI Summary
CRISPR Therapeutics receives conditional marketing authorization from the European Commission for CASGEVY, a gene-edited therapy for severe sickle cell disease and transfusion-dependent beta thalassemia. Over 8,000 eligible patients in the EU may benefit from this approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
none
-
News

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

Rhea-AI Summary
The U.S. FDA has approved CASGEVY, a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia in patients 12 years and older. CRISPR Therapeutics, the biopharmaceutical company behind the treatment, is working with Vertex Pharmaceuticals to establish a network of treatment centers throughout the U.S. to offer CASGEVY to eligible patients. This approval reflects the power and versatility of the CRISPR platform to bring potentially curative treatment options to patients suffering from devastating diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
none
News

CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook

Rhea-AI Summary
CRISPR Therapeutics (CRSP) highlights 2024 outlook, strategic priorities, and recent achievements, including the first-ever approval of a CRISPR-based gene-editing therapy and entering the clinic with in vivo therapies. The company plans to expand its pipeline, drive clinical trials, and innovate on its platform with next-generation gene editing and delivery technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none

FAQ

What is the current stock price of CRISPR Therapeutics (CRSP)?

The current stock price of CRISPR Therapeutics (CRSP) is $38.65 as of December 30, 2024.

What is the market cap of CRISPR Therapeutics (CRSP)?

The market cap of CRISPR Therapeutics (CRSP) is approximately 3.3B.

What is CRISPR Therapeutics AG?

CRISPR Therapeutics AG is a gene editing company focused on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 platform.

What does the CRISPR/Cas9 platform do?

CRISPR/Cas9 is a revolutionary gene editing technology that enables precise, directed changes to genomic DNA, allowing for the treatment of genetically defined diseases.

Where is CRISPR Therapeutics headquartered?

CRISPR Therapeutics is headquartered in Zug, Switzerland, with additional offices in the U.S. and the UK.

What is Casgevy?

Casgevy is a therapeutic developed by CRISPR Therapeutics in collaboration with Vertex Pharmaceuticals, targeting sickle cell disease and transfusion-dependent beta-thalassemia.

What types of diseases is CRISPR Therapeutics targeting?

CRISPR Therapeutics is targeting a range of diseases including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

Who are CRISPR Therapeutics' key partners?

CRISPR Therapeutics has established strategic collaborations with companies like Bayer, Vertex Pharmaceuticals, and ViaCyte, Inc.

What are some of CRISPR Therapeutics' current projects?

Current projects include advancing gene editing programs for immuno-oncology and developing stem cell-derived therapies for Type 1 diabetes.

Where are CRISPR Therapeutics' R&D operations based?

The company's R&D operations are based in Cambridge, Massachusetts.

How has CRISPR Therapeutics impacted the field of medicine?

CRISPR Therapeutics is at the forefront of the gene editing revolution, developing innovative therapies for serious diseases and collaborating with leading companies.

Where can I find more information about CRISPR Therapeutics?

More information about CRISPR Therapeutics can be found on their website at www.crisprtx.com.
Stock CRSP logo
CRISPR Therapeutics AG

Nasdaq:CRSP

CRSP Rankings

#1577 Ranked by Market Cap
N/A Ranked by Dividends

CRSP Stock Data

3.28B
83.90M
1.69%
74.71%
21.27%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
ZUG